Pilot investigations into the mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy.

ABSTRACT:

Background

Dysferlinopathies are a clinically heterogeneous group of muscular dystrophies caused by gene mutations resulting in deficiency of the membrane-associated protein dysferlin. They manifest post-growth and are characterised by muscle wasting (primarily in the limb and limb-gridle muscles), inflammation, and replacement of myofibres with adipose tissue. The precise pathomechanism for dysferlinopathy is currently unclear; as such there are no treatments currently available. Glucocorticoids (GCs) are widely used to reduce inflammation and treat muscular dystrophies, but when administered to patients with dysferlinopathy, they have unexpected adverse effects, with accelerated loss of muscle strength.

Methods

To investigate the mechanistic basis for the adverse effects o

SUBMITTER: Lloyd EM 

PROVIDER: S-EPMC11312411 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature